Ot­su­ka Phar­ma snags a late-stage AD­HD drug in $250M Neu­rovance buy­out

Sev­en months af­ter Neu­rovance cleared its last mid-stage hur­dle for its AD­HD drug, the small Cam­bridge, MA-based biotech is be­ing plucked by Ot­su­ka Phar­ma­ceu­ti­cal in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER